Effectiveness and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Figure 6

Forest plot of adverse events, serious adverse events of any cause, nausea, headache, dermatitis atopic, nasopharyngitis, and upper respiratory tract infection (100 mg abrocitinib vs. placebo).